Product Description
Mechanisms of Action: 5-HT2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location:
Company CEO: John V. Oyler
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hemorrhoids
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01483833 |
VEN309-SMPEC-001 | P2 |
Completed |
Hemorrhoids |
2002-08-01 |
2019-03-19 |
||
NCT01355874 |
VEN309 | P3 |
Terminated |
Hemorrhoids |
2012-06-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|